Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use Disorder and Alcohol-related Disorders (UT2)

 

This Funding Opportunity Announcement (FOA) directed to Small Business Technology Transfer (STTR) applicants is dedicated to the development of therapeutic agents for disorders that fall under the mission of NIAAA.An identified candidate, having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the Small Business Technology Transfer (STTR) clinical application, is required prior to application. The FOA supports Investigational New Drug (IND)-enabling studies for the therapeutic candidate. At the end of the funding period, a successful project should have, at a minimum, an IND application submitted to the U.S. Food and Drug Administration (FDA). The program supports early-phase clinical trials, although these are not required.

Active PAR-15-153 Agency: Department of Health and Human Services
Office: National Institutes of Health Cooperative Agreement Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. 12/11/2017 This program does not have cost sharing or matching requirements. NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
http://grants.nih.gov/grants/guide/pa-files/PAR-15-153.html FBOWebmaster@OD.NIH.GOV $0.00